Advanced Glycation End Products Modulate Structure and Drug Binding Properties of Albumin

Molecular Pharmaceutics

Volumn 12, Issue 9, 2015, Pages 3312-3322

  Awasthi, Saurabh ^a   Murugan, N Arul ^b   Saraswathi, N T ^a  

^a SASTRA UNIVERSITY   (India)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

advanced glycation end products; albumin; argpyrimidine; carboxyethyllysine; diabetes; drug binding affinity; molecular dynamics simulation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ARGPYRIMIDINE; BOVINE SERUM ALBUMIN; CARBOXYETHYLLYSINE; IBUPROFEN; LYSINE DERIVATIVE; PYRIMIDINE DERIVATIVE; TOLBUTAMIDE; UNCLASSIFIED DRUG; LYSINE; N(6)-CARBOXYMETHYLLYSINE; ORNITHINE; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; DRUG BINDING; DRUG BINDING SITE; DRUG STRUCTURE; IN VITRO STUDY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SIMULATION; ANALOGS AND DERIVATIVES; ANIMAL; BINDING SITE; BOVINE; CHEMISTRY; CIRCULAR DICHROISM; GLYCOSYLATION; METABOLISM; PROTEIN CONFORMATION;

ANIMALS; BINDING SITES; CATTLE; CIRCULAR DICHROISM; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; LYSINE; MOLECULAR DYNAMICS SIMULATION; ORNITHINE; PROTEIN BINDING; PROTEIN CONFORMATION; PYRIMIDINES; SERUM ALBUMIN, BOVINE;

EID: 84941083634     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00318     Document Type: Article

References (42)

1. Ramos-Fernandez, E.; Tajes, M.; Palomer, E.; Ill-Raga, G.; Bosch-Morato, M.; Guivernau, B.; Roman-Degano, I.; Eraso-Pichot, A.; Alcolea, D.; Fortea, J.; Nunez, L.; Paez, A.; Alameda, F.; Fernandez-Busquets, X.; Lleo, A.; Elosua, R.; Boada, M.; Valverde, M. A.; Munoz, F. Z. Posttranslational nitro-glycative modifications of albumin in Alzheimers disease: implications in cytotoxicity and amyloid-beta peptide aggregation J. Alzheimer's Dis. 2014, 40, 643-657 10.3233/JAD-130914
2. Obrosova, I. G.; Chung, S. S.; Kador, P. F. (2010) Diabetic cataracts: mechanisms and management Diabetes/Metab. Res. Rev. 2010, 26, 172-180 10.1002/dmrr.1075
3. Hipkiss, A. R. Aging risk factors and Parkinson's disease: contrasting roles of common dietary constituents Neurobiol. Aging 2014, 35 (6) 1469-72 10.1016/j.neurobiolaging.2013.11.032
4. Aubert, C. E.; Michel, P. L.; Gillery, P.; Jaisson, S.; Fonfrede, M.; Morel, F.; Hartemann, A.; Bourron, O. Association of peripheral neuropathy with circulating advanced glycation end products, soluble receptor for advanced glycation end products and other risk factors in patients with type 2 diabetes Diabetes/Metab. Res. Rev. 2014, 30, 679-85 10.1002/dmrr.2529
5. Nimbalkar, V. V.; Mandlik, R. V.; Naik, S. R.; Maseeh, A. Nonenzymatic glycosylation: A biochemical link between chronic hyperglycemia and pathophysiologic processes associated with diabetic complications and aging related debilities Biomed. Aging Pathol. 2012, 2, 133-142 10.1016/j.biomag.2012.08.001
6. Singh, R.; Barden, A.; Mori, T.; Beilin, L. Advanced glycation end-products: a review Diabetologia 2001, 44, 129-46 10.1007/s001250051591
7. Nagai, R.; Matsumoto, K.; Ling, X.; Suzuki, H.; Araki, T.; Horiuchi, S. Glycolaldehyde, a reactive intermediate for advanced glycation end products, plays an important role in the generation of an active ligand for the macrophage scavenger receptor Diabetes 2005, 49, 1714-23 10.2337/diabetes.49.10.1714
8. Gomes, R.; Sousa Silva, M.; Quintas, A.; Cordeiro, C.; Freire, A.; Pereira, P.; Martins, A.; Monteiro, E.; Barroso, E.; Ponces Freire, A. Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy Biochem. J. 2005, 385, 339-345 10.1042/BJ20040833
9. Kim, J.; Kim, O. S.; Kim, C.-S.; Sohn, E.; Jo, K.; Kim, J. S. Accumulation of argpyrimidine, a methylglyoxal-derived advanced glycation end product, increases apoptosis of lens epithelial cells both in vitro and in vivo Exp. Mol. Med. 2012, 44, 167-75 10.3858/emm.2012.44.2.012
10. Shipanova, I. N.; Glomb, M. A.; Nagaraj, R. H. Protein modification by methylglyoxal: chemical nature and synthetic mechanism of a major fluorescent adduct Arch. Biochem. Biophys. 1997, 344, 29-36 10.1006/abbi.1997.0195
11. Oya, T.; Hattori, N.; Mizuno, Y.; Miyata, S.; Maeda, S.; Osawa, T.; Uchida, K. Methylglyoxal modification of protein. Chemical and immunochemical characterization of methylglyoxal arginine adducts J. Biol. Chem. 1999, 274, 18492-502 10.1074/jbc.274.26.18492
12. Ahmed, N.; Dobler, D.; Dean, M.; Thornalley, P. J. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding esterase activity J. Biol. Chem. 2005, 280, 5724-32 10.1074/jbc.M410973200
13. Van Heijst, J. W. J.; Niessen, H. W. M.; Hoekman, K.; Schalkwijk, C. G. Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl) lysine and argpyrimidine Ann. N.Y. Acad. Sci. 2005, 1043, 725-33 10.1196/annals.1333.084
14. Mendez, J. D.; Xie, J.; Aguilar-Hernandez, M.; Mendez-Valenzuela, V. Molecular susceptibility to glycation and its implications in diabetes mellitus and related diseases Mol. Cell. Biochem. 2010, 344, 185-93 10.1007/s11010-010-0541-3
15. Fanali, G.; di Masi, A.; Trezza, V.; Marino, M.; Fasano, M.; Ascenzi, P. Human serum albumin: from bench to bedside Mol. Aspects Med. 2012, 33, 209-90 10.1016/j.mam.2011.12.002
16. Anguizola, J.; Matsuda, R.; Barnaby, O. S.; Hoy, K. S.; Wa, C.; DeBolt, E.; Koke, M.; Hage, D. S. Review: Glycation of human serum albumin Clin. Chim. Acta 2013, 425, 64-76 10.1016/j.cca.2013.07.013
17. Zsila, F. Subdomain IB is the third major drug binding region of human serum albumin: toward the three-sites model Mol. Pharmaceutics 2013, 10, 1668-82 10.1021/mp400027q
18. Curry, S.; Mandelkow, H.; Brick, P.; Franks, N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites Nat. Struct. Biol. 1998, 5, 827-35 10.1038/1869
19. Sudlow, G.; Birkett, D. J.; Wade, D. N. Further characterization of specific drug binding sites on human serum albumin Mol. Pharmacol. 1976, 12, 1052-61
20. Watanabe, H.; Tanase, S.; Nakajou, K.; Maruyama, T.; Kragh-Hansen, U.; Otagiri, M. Role of Arg-410 and Tyr-411 in human serum albumin for ligand binding and esterase-like activity Biochem. J. 2000, 349, 813-9 10.1042/bj3490813
21. Baraka-Vidot, J.; Guerin-Dubourg, A.; Bourdon, E.; Rondeau, P. Impaired drug-binding capacities of in vitro and in vivo glycated albumin Biochimie 2012, 94, 1960-7 10.1016/j.biochi.2012.05.017
22. Klepeis, J. L.; Lindorff-Larsen, K.; Dror, R. O.; Shaw, D. E. Long-timescale molecular dynamics simulations of protein structure and function Curr. Opin. Struct. Biol. 2009, 19, 120-7 10.1016/j.sbi.2009.03.004
23. Vane, J. R.; Botting, R. M. Anti-inflammatory drugs and their mechanism of action Inflammation Res. 1998, 47, 78-87 10.1007/s000110050284
24. Ghuman, J.; Zunszain, P. A.; Petitpas, I.; Bhattacharya, A. A.; Otagiri, M.; Curry, S. Structural basis of the drug-binding specificity of human serum albumin J. Mol. Biol. 2005, 353, 38-52 10.1016/j.jmb.2005.07.075
25. Ahmed, N.; Argirov, O. K.; Minhas, H. S.; Cordeiro, C. A. A.; Thornalley, P. J. Assay of advanced glycation endproducts (AGEs): surveying AGEs by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and application to Nepsilon-carboxymethyl-lysine- and Nepsilon-(1-carboxyethyl)lysine-modified albumin Biochem. J. 2002, 364, 1-14 10.1042/bj3640001
26. Smith, R. E.; MacQuarrie, R. A sensitive fluorometric method for the determination of arginine using 9,10-phenanthrenequinone Anal. Biochem. 1978, 90, 246-55 10.1016/0003-2697(78)90029-5
27. Cayot, P.; Tainturier, G. The quantification of protein amino groups by the trinitrobenzenesulfonic acid method: a reexamination Anal. Biochem. 1997, 249, 184-200 10.1006/abio.1997.2161
28. Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Walker, R. C.; Zhang, W.; Merz, K. M.; Roberts, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Swails, J.; Gotz, A. W.; Kolossvary, I.; Wong, K. F.; Paesani, F.; Vanicek, J.; Wolf, R. M.; Liu, J.; Wu, X.; Brozell, S. R.; Steinbrecher, T.; Gohlke, H.; Cai, Q.; Ye, X.; Wang, J.; Hsieh, M.-J.; Cui, G.; Roe, D. R.; Mathews, D. H.; Seetin, M. G.; Salomon-Ferrer, R.; Sagui, C.; Babin, V.; Luchko, T.; Gusarov, S.; Kovalenko, A.; Kollman, P. A. AMBER 12; University of California: San Francisco, 2012.
29. Volkamer, A.; Kuhn, D.; Rippmann, F.; Rarey, M. DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment Bioinformatics 2012, 28, 2074-5 10.1093/bioinformatics/bts310
30. Trott, O.; Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading J. Comput. Chem. 2010, 31, 455-461 10.1002/jcc.21334
31. Nakajou, K.; Watanabe, H.; Kragh-Hansen, U.; Maruyama, T.; Otagiri, M. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants Biochim. Biophys. Acta, Gen. Subj. 2003, 1623, 88-97 10.1016/j.bbagen.2003.08.001
32. Rondeau, P.; Bourdon, E. The glycation of albumin: structural and functional impacts Biochimie 2011, 93, 645-58 10.1016/j.biochi.2010.12.003
33. Guerin-Dubourg, A.; Catan, A.; Bourdon, E.; Rondeau, P. Structural modifications of human albumin in diabetes Diabetes Metab. 2012, 38, 171-8 10.1016/j.diabet.2011.11.002
34. Khodarahmi, R.; Karimi, S. A.; Ashrafi Kooshk, M. R.; Ghadami, S. A.; Ghobadi, S.; Amani, M. Comparative spectroscopic studies on drug binding characteristics and protein surface hydrophobicity of native and modified forms of bovine serum albumin: possible relevance to change in protein structure/function upon non-enzymatic glycation Spectrochim. Acta, Part A 2012, 89, 177-86 10.1016/j.saa.2011.12.058
35. Sekula, B.; Zielinski, K.; Bujacz, A. Crystallographic studies of the complexes of bovine and equine serum albumin with 3,5-diiodosalicylic acid Int. J. Biol. Macromol. 2013, 60, 316-24 10.1016/j.ijbiomac.2013.06.004
36. Bujacz, A.; Zielinski, K.; Sekula, B. Structural studies of bovine, equine, and leporine serum albumin complexes with naproxen Proteins: Struct., Funct., Genet. 2014, 82, 2199-208 10.1002/prot.24583
37. Maiti, R.; Van Domselaar, G. H.; Zhang, H.; Wishart, D. S. SuperPose: a simple server for sophisticated structural superposition Nucleic Acids Res. 2004, 32, W590-W594 10.1093/nar/gkh477
38. Blache, D.; Bourdon, E.; Salloignon, P.; Lucchi, G.; Ducoroy, P.; Petit, J. M.; Verges, B.; Lagrost, L. Glycated albumin with loss of fatty acid binding capacity contributes to enhanced arachidonate oxygenation and platelet hyperactivity: relevance in patients with type 2 diabetes Diabetes 2015, 63, 960-72 10.2337/db14-0879
39. Joseph, K. S.; Anguizola, J.; Hage, D. S. Binding of tolbutamide to glycated human serum albumin J. Pharm. Biomed. Anal. 2011, 54, 426-32 10.1016/j.jpba.2010.09.003
40. Sudlow, G.; Birkett, D. J.; Wade, D. N. The characterization of two specific drug binding sites on human serum albumin Mol. Pharmacol. 1975, 11, 824-32
41. Epps, D. E.; Raub, T. J.; Caiolfa, V.; Chiari, A.; Zamai, M. Determination of the affinity of drugs toward serum albumin by measurement of the quenching of the intrinsic tryptophan fluorescence of the protein J. Pharm. Pharmacol. 1999, 51, 41-8 10.1211/0022357991772079
42. Pan, X.; Liu, R.; Qin, P.; Wang, Li.; Zhao, X. Spectroscopic Studies on the Interaction of Acid Yellow With Bovine Serum Albumin J. Lumin. 2010, 130, 611-617 10.1016/j.jlumin.2009.11.004